The global hemostats market reached a value of US$ 3.1 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 4.4 Billion by 2027, exhibiting a CAGR of 6% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Hemostats are used to compress blood vessels and prevent the flow of blood or other fluids. They are generally used in adjunct to surgical procedures to manage bleeding. Hemostatic agents offer various benefits, including decreased wound healing and operative time, better management of anticoagulated patients, and reduction in the patient recovery period. A wide range of surgical hemostatic agents is available in the market that vary widely in their composition, cost, immunogenicity, mechanism of action, application and adherence.

On account of the significant rise in the prevalence of chronic disorders, cesarean deliveries, fatal injuries and major organ surgeries, there has been an increasing demand for hemostats. These agents help prevent blood loss during surgical procedures, particularly for nonanatomic and sensitive structures, and among patients with hemostatic abnormalities. Besides this, their use helps in lowering the cost of the procedure, which has led to their rapid adoption among healthcare providers. Moreover, with technological advancements, leading manufacturers have developed absorbable adjunctive hemostats that help professionals to control disruptive bleeding more efficiently as compared to traditional methods. Additionally, they are utilizing nano- and micro-materials for treating uncontrolled hemorrhage and internal bleeding. Market players have also introduced advanced laparoscopic hemostats designed to enhance the quality of surgical operations and allow for less invasive procedures. Along with these developments, improvements in healthcare facilities and extensive research and development (R&D) activities to launch new products, are providing a positive impact on the industry.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global hemostats market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product, application and formulation.

Breakup by Product:

Thrombin Based
Combination Based
Oxidized Regenerated Cellulose Based
Gelatin Based
Collagen Based

Breakup by Application:

Orthopedic Surgery
General Surgery
Neurological Surgery
Cardiovascular Surgery
Reconstructive Surgery
Gynecological Surgery

Breakup by Formulation:

Matrix and Gel Hemostats
Sheet and Pad Hemostats
Sponge Hemostats
Powder Hemostats

Breakup by Region:

North America
United States
Asia Pacific
South Korea
United Kingdom
Latin America
Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Arch Therapeutics Inc., Baxter International Inc., B. Braun Melsungen Aktiengesell, C. R. Bard Inc., GELITA MEDICAL GmbH, Integra LifeSciences Corporation, Johnson & Johnson, Pfizer Inc., Stryker Corporation, Teleflex Incorporated and Z-Medica LLC. Key Questions Answered in This Report:
How has the global hemostats market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global hemostats market?
What are the key regional markets?
What is the breakup of the market based on the product?
What is the breakup of the market based on the application?
What is the breakup of the market based on the formulation?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global hemostats market and who are the key players?
What is the degree of competition in the industry?